LRG1 and colorectal cancer: The plasma levels of core-fucosylated LRG1 were found to be elevated in oral cancer patients relative to normal cases; moreover, the serum levels of LRG1 with fucosylated triantennary N-glycan was identified as a new marker to distinguish colorectal cancer patients from healthy, with a sensitivity and specificity exceeding CA19-9 [46,47].